Nab-rapamycin (** Currently investigational - no approved brand names available. Developed by Aadi Biosciences under the designation ABI-009. **)
Other Medications
Description
Nab-rapamycin (also known as ABI-009) is an investigational drug currently being studied in clinical trials. It is a type of mTOR inhibitor. In the context of colorectal cancer, it has been studied in combination with nivolumab (Opdivo) in patients with advanced MSI-H/dMMR metastatic colorectal cancer. The goal of the clinical trial (NCT03190174) was to determine the maximum safe dose of nab-rapamycin when given after nivolumab and to see how effective this combination is in controlling the cancer and extending the time without disease progression (progression-free survival). It is important to note that this drug is still in early-phase trials and is not yet approved for treating colorectal cancer or any other cancer.
Mechanism of Action
Nab-rapamycin is an mTOR inhibitor. mTOR (mammalian target of rapamycin) is a protein that plays a key role in cell growth, division, and survival. By inhibiting mTOR, nab-rapamycin aims to block these processes in cancer cells, potentially slowing or stopping their growth. In the trial mentioned, it was used in combination with nivolumab, an immunotherapy drug that helps the immune system recognize and attack cancer cells. The combination aims to target both the cancer cells directly (via mTOR inhibition) and stimulate the immune system against them.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.